Online Livestream
3rd Virtual
3rd VirtualClinical Trials
What To Expect

The 3rd Virtual Clinical Trials Conference is the industry’s recognized leading event for overcoming technology barriers, accelerating the adoption of digital trials, and building team capabilities around these now-essential methods. Our speaking faculty of over 25 industry thought-leaders guide you through the necessary changes in your clinical infrastructure, while emphasizing how to always put patients first. No other event offers so many all-new insights on comparing methods for virtual studies, rising to the challenges of incorporating AI into remote trials, and reorienting virtual trial design around the patient perspective. Join us to revolutionize your clinical research pipeline – and turn today’s emergency into tomorrow’s opportunity.

Conference
New Topics
Featured Speakers
Alicia Staley
Medidata, a Dassault Systèmes company
Senior Director, Patient Engagement
Alka Shaunik
CSL BEHRING
Global Therapy Area Head, Cardiovascular & Metabolism, Medical Affairs
Bibhudatta Mishra
JOHNS HOPKINS MEDICINE
Senior Clinical Trial Scientist
Claus Torp Jensen
MEMORIAL SLOAN KETTERING CANCER CENTER
Chief Digital Officer and Chief Technology Officer
Craig Lipset
CLINICAL INNOVATION PARTNERS
Founder
Daniella Hensley
JANSSEN
Director, Global Clinical Operations
Dimitri Talantov
JANSSEN
Sr. Director Medical Affairs Clinical Trial Innovation
Elizabeth Stoner
ALLOVIR
Senior Clinical Advisor
Emily Kunka
UCB
Digital Transformation Project Lead
Hassan Kadhim
BRISTOL MYERS SQUIBB
Director, Global Head of Clinical Trial Business Capabilities and Clinical Innovation
Jen Horonjeff
SAVVY COOPERTIVE
Patient Advocate, Founder and CEO
John Reites
THREAD
CEO
Lesley Schofield
NOVARTIS
Director of Clinical Trial Operations, U S Medical Affairs
Lorena Kuri
BRISTOL-MYERS SQUIBB
Head, Diversity Strategy
Maimah Karmo
TIGERLILY FOUNDATION
Patient Advocate, CEO
Michael Song
ASTRAZENECA
Senior Manager, Head of Device Functionality, Safety, and Digital Connectivity
Michael Tucker
Medidata, a Dassault Systèmes company
Senior Product Solutions Specialist
Michelle Luo
TAKEDA
Head of Global Evidence & Outcomes
Mike Collins
AKEBIA THERAPEUTICS
Senior VP, Clinical Operations & Data Sciences
Nancy Sacco
MEITHEAL SPECIALTY PHARMA
VP, Clinical Development
Nina Renner-Thomas
JUUL Labs
Clinical Project Lead, Manager, Clinical Operations
Safwan Kezbor
SHIONOGI
Medical Director, Clinical Development
Shameer Khader
ASTRAZENECA
Senior Director, Data Science, Digital Health, and Bioinformatics
Sharon Terry
Genetic Alliance
Patient Advocate, Founder and CEO
T.J. Sharpe
TJSharpe.com
Patient Advocate
Vanessa Gertsen
BRISTOL-MYERS SQUIBB
Head, Recruitment Strategy, Clinical Trial Engagement & Enrollment
Wendy Wu
JAZZ PHARMACEUTICALS
Director, Clinical Development
Event Schedule
  • Communicate the level of validation needed in order to make claims on data
  • Upgrade due diligence around the technologies that clinical trial teams must have in place
  • Bridge gaps in levels of inherent knowledge
  • Explore select differences in launching hybrid decentralized studies in Europe, Asia Pacific and South America
  • Discuss flexible approaches for eConsent, telehealth, eCOA sensors and home health
  • Review lessons learned to date with global DCT expansion
  • Reduce the need for site visits through at-home monitoring
  • Gather and reliably archive patient feedback on drug formulation and delivery
  • Turn a challenging time into new opportunity, with trial structures that more easily fit into patients’ routines
  • Explore the potential of remote models
  • Recognize and adapt to burdens and complexities of multiple stakeholders
  • Evaluate vendor capabilities to move beyond virtual sites and take on both CRO and site capabilities
  • Understand the regulatory guidance available and consider the implications to the regulatory strategy for products that use these novel approaches in clinical trials.
  • Utilize novel approaches to clinical trials within a context of COVID-19
  • Explore the US FDA guidance documents published related to COVID-19 pandemic and provide regulatory insights as to moving forward in our ‘new normal’ of clinical trial development.
  • Leverage a single destination for all trial virtualization technologies
  • Incorporate and harness the patient voice in the design of a decentralized trial
  • Improve patient access to clinical trials using registries
  • Review how the industry combines conventional strategies with virtual trials
  • Restructure internal processes as needed for implementation
  • Investigate the most cost-effective applications and outcomes
  • Analyze how digital health tools can move trials forward
  • Ensure the data integrity and subjects' safety monitoring in the virtual clinical trials implementation
  • Explore areas requiring change in order to drive sustaining adoption in the organization
  • Discuss specific examples spanning processes, vendor selection, training and protocol authoring
  • Share experiences managing organizational change to recognize pitfalls and drivers of success
  • Hear the insights gained from designing and implementing transformational solutions for the new era that will propel the future of drug development
  • Discover how to use a lens of business-to-consumer product evolution
  • Examine actual client needs from this past year as case studies showing how we can shape an “Amazon experience”
  • Identify and increase focus on patients and evolving customer needs to deliver solutions that are relevant and long-lasting
  • Outline how the proper technology choices can help or hinder you
  • Compare and contrast technical platform options
  • Focus on the clinical trial without commercial consideration
  • Evaluate the benefits of virtual meetings in terms of cost and convenience
  • Compare different methods for gathering information through “breakouts
  • Review new outreach options for CRAs and training
  • Clarify in advance the needs for tech support
  • Explore the most up-to-date options for large-scale data analysis for virtual trials
  • Address common mistakes and misperceptions
  • Clarify what is realistically possible for digital health and bioinformatics in a remote setting
  • Determine the most important indicators of site quality
  • Plan creative collaboration and flexible strategies
  • Find the fastest techniques for site quality maximization
  • Recognize how behavior influences team results
Register Now

This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.

Subscribe to Conference Updates
Join our e-newsletter list to follow closely all news.
Event Sponsors
Event Partners
15
Speakers
21
Days
251
Participants
125
Workshops
90
Venue
Contact Us